Core Insights - Malibu Boats and Axis Wake received recognition through the Marine Industry Customer Satisfaction Index (CSI) Program, highlighting their performance in product quality and craftsmanship [1][2] - The recognition was awarded at the 2026 Miami International Boat Show, emphasizing the importance of customer feedback during the first year of boat ownership [2] - The CSI Program, administered by the National Marine Manufacturers Association (NMMA), evaluates satisfaction across various ownership touchpoints, including purchase process, delivery experience, product quality, and service support [2] Company Performance - The recognition reflects the engineering excellence, vertical integration, and consistent manufacturing practices of Malibu and Axis [1][3] - Rachael Green, Senior Vice President of Operations & Engineering, stated that the goal is to build the best boats and provide a world-class ownership experience, supported by high standards in manufacturing and dealer partnerships [3] Company Overview - Malibu Boats, Inc. is headquartered in Loudon, Tennessee, and designs, engineers, manufactures, and markets a portfolio of recreational powerboat brands, including Malibu Boats and Axis Wake [4]

Appointment within the Board of Directors of EDF The Board of Directors meeting held on 19 February 2026 co-opted Martin Briens, Secretary General of the French Ministry for Europe and Foreign Affairs, as a Director, replacing Anne-Marie Descôtes for the remaining of her term of office, i.e. until the end of the General Meeting ruling on the accounts for the fiscal year ending 31 December 2026. Martin Briens is appointed, effective as of today, on the recommendation of the State, pursuant to Article 6.II of ...

Maranello (Italy), February 19, 2026 - Ferrari N.V. (NYSE/EXM: RACE) announced today that it has published its 2025 Annual Report and filed with the United States Securities and Exchange Commission its annual report on Form 20-F, including financial statements for the fiscal year ended December 31, 2025. The 2025 Sustainability Statement, prepared in accordance with the requirements from the European Sustainability Reporting Standard (ESRS) on a voluntary basis, is included in the 2025 Annual Report. Ferrar ...

Hagar hf. luku í dag útboði á nýjum 6 mánaða víxlaflokki HAGA260826. Heildartilboð í flokkinn námu samtals 1.100 m.kr. að nafnvirði á flötu vöxtunum 7,65% - 7,90%. Tilboðum að fjárhæð 840 m.kr. var tekið á 7,75% flötum vöxtum. Útgáfudagur og uppgjör viðskipta er 26. febrúar 2026. Stefnt er að töku til viðskipta á Nasdaq Iceland. Fossar fjárfestingarbanki hf. hefur umsjón með útgáfu og sölu víxlanna sem og töku þeirra til viðskipta á markaði Nasdaq Iceland. Nánari upplýsingar veita: Ásgrímur Gunnarsson, Fos ...

Core Viewpoint - UFP Technologies, Inc. is set to report its fourth quarter and year-end results on February 24, 2026, with a conference call scheduled for February 25, 2026, at 8:30 AM ET to discuss these results [1][2]. Company Overview - UFP Technologies, Inc. is a contract development and manufacturing organization that specializes in single-use and single-patient medical devices [3]. - The company plays a crucial role in the medical device supply chain and serves as a valued outsourcing partner for leading medical device manufacturers [3]. - Its products are utilized in various medical applications, including minimally invasive surgery, infection prevention, wound care, wearables, orthopedic soft goods, and orthopedic implants [3].

CORONA, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Monster Beverage Corporation (NASDAQ: MNST) announced today that results for its fourth quarter ended December 31, 2025, will be reported on Thursday, February 26, 2026, after the close of the market. The company also said that Chief Executive Officer, Hilton Schlosberg, will host an investor conference call that same day at 2 p.m. Pacific Time to review the company’s financial results and operations. The call will be open to all interested investors through ...

Core Viewpoint - Tallinna Sadam is hosting an investor conference webinar to present its unaudited results for Q4 and the full year of 2025, scheduled for February 26, 2026 [1] Group 1: Webinar Details - The webinar will be conducted on the Microsoft Teams platform in two languages: Estonian at 10:00 EET and English at 11:00 EET [1] - The Chairman of the Management Board, Valdo Kalm, and the Head of Investor Relations, Angelika Annus, will present the results and address questions from participants [1] - Participants are encouraged to submit questions in advance due to time limitations [1] Group 2: Company Overview - Tallinna Sadam is one of the largest cargo and passenger port complexes in the Baltic Sea region, providing both passenger and freight services [3] - The company operates in the shipping business through subsidiaries, including OÜ TS Laevad, which offers ferry services, and OÜ TS Shipping, which charters the multifunctional vessel Botnica for icebreaking and offshore services [3] - Tallinna Sadam is also a shareholder in AS Green Marine, which provides waste management services [3]

Core Insights - INmune Bio Inc. is hosting a webinar on February 26, 2026, to discuss CORDStrom for treating recessive dystrophic epidermolysis bullosa (RDEB) and present new data from the MissionEB clinical study [1][2] Group 1: CORDStrom Overview - CORDStrom™ is a patent-pending cell medicine made from aseptic, allogeneic, pooled human umbilical cord-derived mesenchymal stromal cells (hucMSCs) designed for injection or infusion [4] - The platform utilizes proprietary techniques for screening, pooling, and expanding hucMSCs, allowing for the creation of off-the-shelf medicines for complex inflammatory and autoimmune diseases [4] - CORDStrom™ products aim to provide consistent, scalable, and affordable cellular medicines with optimized characteristics for various indications [4] Group 2: Clinical Trial Insights - The upcoming webinar will highlight the systemic disease-modifying capabilities of CORDStrom™ in RDEB patients, contrasting it with current standard-of-care options that focus on topical treatments [2] - Key clinical benchmarks to be discussed include improvements in the EBDASI (EB Disease Activity and Scarring Index), nutritional and weight gain data in pediatric patients, reductions in pain and itch, and enhancements in quality of life [6] - Principal investigators, including Dr. Anna Martinez and Prof. Mark Lowdell, will provide insights from the MissionEB study, emphasizing the systemic nature of RDEB and the scientific rationale for using CORDStrom™ [6][3] Group 3: Company Background - INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments targeting the innate immune system, with three product platforms: CORDStrom™, XPro™, and INKmune® [7] - The company is publicly traded on NASDAQ under the ticker INMB and is dedicated to advancing therapies for various diseases [7]

Paris, 19 February 2026, 6:00pm The 2025 full-year results will be released on Thursday 12 March 2026 before market opening (instead of Thursday 12 March 2026 after market close). The audio webcast for analysts and investors will be held on Thursday 12 March 2026 at 9:30 am (Paris time). The other dates of the 2026 financial calendar remain unchanged. Press Contact Analyst Contact RUBIS - Communication departmentRUBIS - Clémence Mignot-Dupeyrot, Head of IRTel: +33 (0)1 44 17 95 95presse@rubis.frTel: +33 ( ...

Primary Mortgage Market Survey® U.S. weekly average mortgage rates as of 02/19/2026 MCLEAN, Va., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Freddie Mac (OTCQB: FMCC) today released the results of its Primary Mortgage Market Survey® (PMMS®), showing the 30-year fixed-rate mortgage (FRM) averaged 6.01%. “Mortgage rates dropped again this week, now down to their lowest level since September of 2022,” said Sam Khater, Freddie Mac’s Chief Economist. “This lower rate environment is not only improving affordability for ...